New drug aims to stop cancer wasting in colorectal patients

NCT ID NCT07033026

Recruiting now Symptom relief Sponsor: NGM Biopharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called NGM120 in people with colorectal cancer who are losing weight due to cancer cachexia. The goal is to see if NGM120 can help patients gain or maintain weight and improve their quality of life. About 136 participants will receive either NGM120 or a placebo every 4 or 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NGM120
What this could lead to: If it works, this could lead to a treatment that helps colorectal cancer patients with cachexia maintain or gain weight and feel better.
What could go wrong: This is an early Phase 2 trial with only 136 participants, so results may not apply to everyone. The drug may not improve weight or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CACHEXIA COLORECTAL CANCER CRC (COLORECTAL CANCER)

Contacts and locations

Locations

NGM Clinical Study Site
RECRUITING

Los Angeles, California, 90033, United States
NGM Clinical Study Site
RECRUITING

Los Angeles, California, 90095, United States
NGM Clinical Study Site
RECRUITING

Santa Rosa, California, 95403, United States
NGM Clinical Study Site
RECRUITING

Margate, Florida, 33063, United States
NGM Clinical Study Site
RECRUITING

Baltimore, Maryland, 21201, United States
NGM Clinical Study Site
RECRUITING

New York, New York, 10065, United States
NGM Clinical Study Site
RECRUITING

Toledo, Ohio, 43608, United States
NGM Clinical Study Site
RECRUITING

Youngstown, Ohio, 44504, United States
NGM Clinical Study Site
RECRUITING

Dallas, Texas, 75390, United States
NGM Clinical Study Site
WITHDRAWN

Kingwood, Texas, 77339, United States
NGM Clinical Study Site
RECRUITING

Laredo, Texas, 78041, United States
NGM Clinical Study Site
RECRUITING

Richmond, Virginia, 23114, United States
NGM Clinical Study Site
RECRUITING

Appleton, Wisconsin, 54915, United States
NGM Clinical Study Site
RECRUITING

Tbilisi, 159, Georgia
NGM Clinical Study Site
RECRUITING

Tbilisi, 159, Georgia
NGM Clinical Study Site
RECRUITING

Tbilisi, 159, Georgia
NGM Clinical Study Site
RECRUITING

Tbilisi, 159, Georgia
NGM Clinical Study Site
RECRUITING

Tbilisi, 186, Georgia
NGM Clinical Study Site
RECRUITING

Goyang, 10326, South Korea
NGM Clinical Study Site
RECRUITING

Goyang, 1048, South Korea
NGM Clinical Study Site
RECRUITING

Incheon, 21565, South Korea
NGM Clinical Study Site
RECRUITING

Seoul, 2841, South Korea
NGM Clinical Study Site
RECRUITING

Seoul, 3080, South Korea
NGM Clinical Study Site
RECRUITING

Seoul, 6351, South Korea
NGM Clinical Study Site
RECRUITING

Suwon, 16247, South Korea
NGM Clinical Study Site
RECRUITING

Taichung, 407216, Taiwan
NGM Clinical Study Site
RECRUITING

Taipei, 100225, Taiwan
NGM Clinical Study Site
RECRUITING

Taoyuan, 333423, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.